Incoming Roche CEO builds out his top team, tapping Genentech vet to lead pharma division
Roche announced another leadership shuffle Thursday morning – the head of global product strategy, Teresa Graham, will take over as CEO of Roche Pharmaceuticals in March while the company’s corporate executive committee will make a spot for Levi Garraway, CMO and executive VP of global product development.
Thomas Schinecker will take over the top spot as Roche group CEO in March, leaving his spot as head of diagnostics.
Garraway is a relatively new 2019 addition to Roche. He was previously named senior vice president of global development and medical affairs for Eli Lilly’s oncology business in 2017.
According to the company’s announcement, Graham started out at Genentech, a subsidiary of Roche, in 2005 in product management and worked her way up through marketing, field reimbursement management and managing “major aspects” of Genentech’s portfolio until she moved into her current position.
She’s taking over for Bill Anderson, who stepped down at the end of 2022 to “pursue opportunities outside of Roche.”
Roche’s newest top leaders have a lot on their plate this spring, with the beginning of a Phase II study for the Huntington’s disease drug tominersen to see whether the drug can slow progression in adults with early-stage symptoms.
The Phase II trial is coming off of the back of a flunked Phase III test of the drug after later-stage patients with the disease seemed to be worse off than those who were on the placebo. The new trial will have lower doses for a shorter period of time.
Graham and Schinecker are also taking over a company with a more consolidated pipeline: the company dumped its combination of ipatasertib and abiraterone after failures in trials for breast and prostate cancer, according to a Q4 update.
Other programs are in the bin as well, including several combinations of its blockbuster cancer drug Tecentriq and the Alzheimer’s candidate gantenerumab, which has repeatedly failed to hit primary endpoints in trials.